Efficacy and Safety of ALT-801 in the Treatment of Obesity

Phase 2 Completed 391 enrolled Altimmune, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.

Timeline

Start: 2022-03-31
Primary completion: 2023-09-28
Completion: 2023-09-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALT-801	Protein / enzyme biologic	—	Subcutaneous

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Summary

Timeline

Drugs

Indications